Skip to main content

Aneurysmal Subarachnoid Hemorrhage

7
Pipeline Programs
6
Companies
9
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
3
0
3
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 10 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Idorsia
IdorsiaSwitzerland - Allschwil
5 programs
2
3
ClazosentanPhase 31 trial
ClazosentanPhase 31 trial
Clazosentan 5 m/hPhase 31 trial
ClazosentanPhase 21 trial
Clazosentan 1 mg/hPhase 21 trial
Active Trials
NCT02560532Completed25Est. May 2017
NCT00111085Completed413Est. Mar 2006
NCT03585270Completed409Est. Nov 2022
+2 more trials
Genentech
GenentechCA - Oceanside
2 programs
1
1
erythropoietin betaPhase 21 trial
SatralizumabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT05727657Withdrawn0Est. Jun 2024
NCT00140010Completed80Est. Mar 2007
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
Aneurysmal Subarachnoid Hemorrhage Multi-Omics Research ProgramN/A1 trial
Active Trials
NCT07270419Recruiting2,000Est. Dec 2027
Fresenius Kabi
Fresenius KabiGermany - Bad Homburg
1 program
Diben 1.5 kcal HPN/A1 trial
Active Trials
NCT02503527Terminated28Est. Sep 2018
Partner Therapeutics
Partner TherapeuticsMA - Lexington
1 program
Diben 1.5 kcal HPN/A
Roche
RocheSTAVANGER NORWAY, Norway
1 program
erythropoietin betaPHASE_2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
IdorsiaClazosentan
IdorsiaClazosentan 5 m/h
IdorsiaClazosentan
IdorsiaClazosentan
Genentecherythropoietin beta
IdorsiaClazosentan 1 mg/h
GenentechSatralizumab
UNION therapeuticsAneurysmal Subarachnoid Hemorrhage Multi-Omics Research Program
Fresenius KabiDiben 1.5 kcal HP

Clinical Trials (9)

Total enrollment: 4,689 patients across 9 trials

NCT03585270IdorsiaClazosentan

Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain

Start: Feb 2019Est. completion: Nov 2022409 patients
Phase 3Completed
NCT00940095IdorsiaClazosentan 5 m/h

Clazosentan in Aneurysmal Subarachnoid Hemorrhage

Start: Jul 2009Est. completion: Jan 2011577 patients
Phase 3Terminated
NCT00558311IdorsiaClazosentan

Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping

Start: Dec 2007Est. completion: Jul 20101,157 patients
Phase 3Completed
NCT02560532IdorsiaClazosentan

Evaluation of the Efficacy and Safety of Clazosentan in Reversing Cerebral Vasospasm in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage

Start: Mar 2016Est. completion: May 201725 patients
Phase 2Completed
NCT00140010Genentecherythropoietin beta

Erythropoietin Therapy for Subarachnoid Hemorrhage

Start: Apr 2005Est. completion: Mar 200780 patients
Phase 2Completed
NCT00111085IdorsiaClazosentan 1 mg/h

Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)

Start: Jan 2005Est. completion: Mar 2006413 patients
Phase 2Completed
NCT05727657GenentechSatralizumab

Satralizumab in Aneurysmal Subarachnoid Hemorrhage

Start: Jun 2024Est. completion: Jun 20240
Phase 1Withdrawn
NCT07270419UNION therapeuticsAneurysmal Subarachnoid Hemorrhage Multi-Omics Research Program

Aneurysmal Subarachnoid Hemorrhage Multi-Omics Research Program

Start: Nov 2023Est. completion: Dec 20272,000 patients
N/ARecruiting
NCT02503527Fresenius KabiDiben 1.5 kcal HP

Efficacy and Safety Study of a Low-carbohydrate Tube Feed in Critically Ill Patients Under Insulin Therapy

Start: Aug 2015Est. completion: Sep 201828 patients
N/ATerminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 4,689 patients
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.